

Erling A Hoivik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7506722/publications.pdf>

Version: 2024-02-01

17
papers

1,475
citations

687363

13
h-index

888059

17
g-index

18
all docs

18
docs citations

18
times ranked

3466
citing authors

#	ARTICLE	IF	CITATIONS
1	An MRI-Based Radiomic Prognostic Index Predicts Poor Outcome and Specific Genetic Alterations in Endometrial Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 538.	2.4	15
2	Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis. <i>Communications Medicine</i> , 2021, 1, .	4.2	20
3	A radiogenomics application for prognostic profiling of endometrial cancer. <i>Communications Biology</i> , 2021, 4, 1363.	4.4	14
4	High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 157, 260-267.	1.4	32
5	<i>PIK3CA</i> Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 334-345.	7.0	17
6	Class I Phosphoinositide 3-Kinase <i>PIK3CA</i> /p110 α and <i>PIK3CB</i> /p110 β Isoforms in Endometrial Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3931.	4.1	26
7	Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer. <i>PLoS ONE</i> , 2018, 13, e0206665.	2.5	11
8	<i>PIK3CA</i> exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. <i>Scientific Reports</i> , 2017, 7, 10240.	3.3	19
9	Endometrial cancer cells exhibit high expression of p110 β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation. <i>Oncotarget</i> , 2017, 8, 3881-3894.	1.8	15
10	A Common Variant at the 14q32 Endometrial Cancer Risk Locus Activates AKT1 through YY1 Binding. <i>American Journal of Human Genetics</i> , 2016, 98, 1159-1169.	6.2	32
11	The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. <i>Nature Genetics</i> , 2016, 48, 848-855.	21.4	174
12	Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. <i>Oncotarget</i> , 2015, 6, 1327-1339.	1.8	50
13	Landscape of genomic alterations in cervical carcinomas. <i>Nature</i> , 2014, 506, 371-375.	27.8	708
14	Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. <i>European Journal of Cancer</i> , 2014, 50, 3003-3010.	2.8	73
15	A Novel Wnt Regulatory Axis in Endometrioid Endometrial Cancer. <i>Cancer Research</i> , 2014, 74, 5103-5117.	0.9	114
16	Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. <i>Oncotarget</i> , 2014, 5, 1052-1061.	1.8	35
17	Lack of Estrogen Receptor- α Is Associated with Epithelial-Mesenchymal Transition and PI3K Alterations in Endometrial Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 1094-1105.	7.0	120